VYNE Therapeutics (VYNE) Competitors $0.30 -0.01 (-3.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.30 +0.00 (+0.27%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE vs. RNTX, MAAQ, RVPH, ITRM, KZR, CLSD, ASBP, CASI, PMN, and TENXShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Rein Therapeutics (RNTX), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), Clearside Biomedical (CLSD), Aspire Biopharma (ASBP), CASI Pharmaceuticals (CASI), Promis Neurosciences (PMN), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Its Competitors Rein Therapeutics Mana Capital Acquisition Reviva Pharmaceuticals Iterum Therapeutics Kezar Life Sciences Clearside Biomedical Aspire Biopharma CASI Pharmaceuticals Promis Neurosciences Tenax Therapeutics VYNE Therapeutics (NASDAQ:VYNE) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk. Does the media refer more to VYNE or RNTX? In the previous week, Rein Therapeutics had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for Rein Therapeutics and 0 mentions for VYNE Therapeutics. Rein Therapeutics' average media sentiment score of 0.59 beat VYNE Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment VYNE Therapeutics Neutral Rein Therapeutics Positive Do insiders & institutionals believe in VYNE or RNTX? 83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 4.8% of VYNE Therapeutics shares are held by insiders. Comparatively, 5.1% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has stronger earnings & valuation, VYNE or RNTX? VYNE Therapeutics has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVYNE Therapeutics$500K15.24-$39.83M-$0.90-0.33Rein TherapeuticsN/AN/A-$62.88M-$2.69-0.49 Which has more risk & volatility, VYNE or RNTX? VYNE Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Do analysts recommend VYNE or RNTX? VYNE Therapeutics currently has a consensus target price of $6.25, indicating a potential upside of 1,988.90%. Given VYNE Therapeutics' higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Rein Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is VYNE or RNTX more profitable? Rein Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -8,097.69%. VYNE Therapeutics' return on equity of -77.57% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VYNE Therapeutics-8,097.69% -77.57% -63.09% Rein Therapeutics N/A -141.11%-33.83% SummaryVYNE Therapeutics beats Rein Therapeutics on 7 of the 13 factors compared between the two stocks. Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.62M$2.60B$5.83B$9.92BDividend YieldN/A50.06%6.70%4.51%P/E Ratio-0.3323.3476.2926.13Price / Sales15.24555.07530.72175.33Price / CashN/A166.6036.9959.28Price / Book0.085.5011.486.09Net Income-$39.83M$32.95M$3.29B$266.51M7 Day Performance-6.65%2.88%1.28%0.45%1 Month Performance-20.66%9.38%8.56%5.05%1 Year Performance-84.25%2.44%61.19%26.03% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics1.8375 of 5 stars$0.30-3.6%$6.25+1,988.9%-84.3%$7.62M$500K-0.3330RNTXRein TherapeuticsN/A$1.39+23.0%N/AN/A$32.39MN/A-0.529Positive NewsGap UpHigh Trading VolumeMAAQMana Capital AcquisitionN/A$3.81+0.5%N/A+1,189.5%$30.96MN/A0.001RVPHReviva Pharmaceuticals2.745 of 5 stars$0.45-2.2%$5.20+1,055.6%-67.5%$30.60MN/A-0.695Gap UpITRMIterum Therapeutics2.822 of 5 stars$0.68-2.2%$9.00+1,229.8%-37.2%$30.22MN/A-0.8010News CoveragePositive NewsShort Interest ↓KZRKezar Life Sciences2.6464 of 5 stars$3.95-0.5%$9.00+127.8%-27.3%$28.93M$7M-0.4160CLSDClearside Biomedical2.2365 of 5 stars$0.37-5.1%$4.20+1,042.9%-64.3%$28.85M$1.66M-0.9930High Trading VolumeASBPAspire BiopharmaN/A$0.58+3.4%N/AN/A$28.49MN/A0.00N/ACASICASI Pharmaceuticals3.7887 of 5 stars$2.31-5.3%$4.00+73.2%-64.0%$28.41M$28.54M-0.80180Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap DownPMNPromis Neurosciences2.84 of 5 stars$0.54+2.7%$4.33+702.6%-66.9%$27.97MN/A-2.575Gap DownTENXTenax Therapeutics1.3407 of 5 stars$5.99+1.0%$17.00+183.8%+62.3%$27.33MN/A-6.519 Related Companies and Tools Related Companies RNTX Competitors MAAQ Competitors RVPH Competitors ITRM Competitors KZR Competitors CLSD Competitors ASBP Competitors CASI Competitors PMN Competitors TENX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYNE) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYNE Stock Alerts